CS
TLIS

Credit Suisse’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Credit Suisse’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4378
2022
Q2 		$0 Buy
+1
New +$16 ﹤0.01% 4420

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's TLIS Position: Q3 2022 in Review

Credit Suisse sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in TLIS in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 29 funds tracked by Wall St. Rank hold TLIS as of Q3 2022.

  • Credit Suisse reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Talis Biomedical Corporation Common Stock share in Q3 2022.
  • Credit Suisse first reported a position in Talis Biomedical Corporation Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Talis Biomedical Corporation Common Stock position peaked at $0 in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.